drugset / Trial / NCT06679374
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Phase 2
Recruiting
102 enrolled
Vikas Kotagal
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.
Timeline
- Start
- 2025-04-09
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 0.5 mg | — |